ReShape Lifesciences (RSLS, Financial) is set to unveil promising pre-clinical findings on its innovative Diabetes Neuromodulation device at the upcoming Minnesota Neuromodulation Symposium in Minneapolis. This research evaluates the effectiveness of hypothalamic ventromedial nucleus stimulation (HVNS) in a Type 1 diabetic swine model, using a laparoscopically placed electrode on the paraventricular nucleus (PVN). Results showed a significant rise in blood glucose levels and glucagon secretion without affecting heart rate. In trials, glucose levels increased from 45 to 58 mg/dL and from 51 to 68 mg/dL within 30 minutes of stimulation in separate subjects. Blood glucagon levels also saw an increase, from 4.1 to 12.3 pmol/L and 3.5 to 7.6 pmol/L, respectively.
Critically, heart rates remained consistent, indicating the absence of cardiac side effects during the procedure. Vomiting was only noted at higher current levels than those required for beneficial glucose modulation, highlighting a safe therapeutic range. Control tests involving intramuscular glucagon injections yielded similar glucose enhancements, emphasizing HVNS's potential as a viable alternative treatment for managing diabetes.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Reshape Lifesciences Inc (RSLS, Financial) is $1.00 with a high estimate of $1.00 and a low estimate of $1.00. The average target implies an upside of 194.99% from the current price of $0.34. More detailed estimate data can be found on the Reshape Lifesciences Inc (RSLS) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Reshape Lifesciences Inc's (RSLS, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
